KR910011891A - 펩티드 화합물, 이의 제조방법 및 이를 함유하는 약학적 조성물 - Google Patents

펩티드 화합물, 이의 제조방법 및 이를 함유하는 약학적 조성물 Download PDF

Info

Publication number
KR910011891A
KR910011891A KR1019900021101A KR900021101A KR910011891A KR 910011891 A KR910011891 A KR 910011891A KR 1019900021101 A KR1019900021101 A KR 1019900021101A KR 900021101 A KR900021101 A KR 900021101A KR 910011891 A KR910011891 A KR 910011891A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
hydroxy
hydrogen
formula
Prior art date
Application number
KR1019900021101A
Other languages
English (en)
Other versions
KR0180223B1 (ko
Inventor
마사끼 마쭈오
다이찌로 하기와라
히로시 미야께
Original Assignee
후지사와 도모기찌로
후지사와 야꾸힝 고교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 후지사와 도모기찌로, 후지사와 야꾸힝 고교 가부시끼가이샤 filed Critical 후지사와 도모기찌로
Publication of KR910011891A publication Critical patent/KR910011891A/ko
Application granted granted Critical
Publication of KR0180223B1 publication Critical patent/KR0180223B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Two-Way Televisions, Distribution Of Moving Picture Or The Like (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

내용 없음

Description

펩티트 화합물, 이의 제조방법 및 이를 함유하는 약학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (16)

  1. 하기 일반식(Ⅰ)의 화합물 및 이의 약학적으로 허용되는 염:
    상기 식에서, R1는 아릴 또는 일반식
    [여기서, X는 CH 또는 N이고, Z은 0 또는 N-R5(R5는 수소 또는 저급 알킬임)이다]이고, R2는 하이드록시 또는 저급 알콕시이고, R3은 수소 또는 적합한 치환기(들)을 가질 수 있는 저급 알킬이고, R4는 적합한 치환기(들)을 가질 수 있는 아르(저급)알킬이고, A는 카르보닐 또는 술포닐이며, Y는 결합이거나 저급 알켄일렌이다.
  2. 제1항에 있어서 R1이 페닐, 벤조푸릴, 인다졸일, 인돌일 또는 1-저급 알킬인돌일이고, R3가 수소, 저급알킬, 하이드록시(저급) 알킬 또는 아실옥시(저급) 알킬이며, R4가 페닐(저급)알킬 또는 할로페닐(저급) 알킬인 화합물.
  3. 제2항에 있어서, R1이 벤조푸릴, 인다졸일, 인돌일 또는 1-저급 알킬인돌일이고, A가 카르보닐이며, Y가 결합인 화합물.
  4. 제3항에 있어서, R1이 벤조푸릴, 인다졸일, 인돌일, 1-메틸인돌릴 또는 1-이소프로필인돌일이고, R2가 하이드록시 또는 메톡시이고, R3가 수소, 메틸, 하이드록시에틸 또는 아세톡시에틸이며, R4가 벤질, 펜에틸, o-플루오로벤질, m-플루오로벤질 또는 p-플루오로벤질인 화합물.
  5. 제4항에 있어서,
    으로 이루어진 그룹 중에서 선택된 화합물.
  6. 제2항에 있어서, R1이 페닐이고, A가 카르보닐 또는 술포닐이며, Y가 저급 알켄일렌인 화합물.
  7. 제6항에 있어서, R2가 하이드록시이고, R3가 메틸이고, R4가 벤질이며, Y가 비닐렌인 화합물.
  8. 제7항에 있어서
    으로 이루어진 그룹중에서 선택된 화합물.
  9. 일반식(Ⅱ)의 화합물 또는 이미노 그룹에서의 이의 반응성 유도체 또는 이의 염을 일반식(Ⅲ)의 화합물 또는 카르복시 그룹이나 술포 그룹에서의 이의 반응성 유도체 또는 이의 염과 반응시키거나; 일반식(Ⅰ-a)의 화합물 또는 이의 염을 R3 a중의 하이드록시 보호그룹의 제거 반응으로 반응시켜 일반식(Ⅰ-b)의 화합물 또는 이의 염을 수득함을 특징으로 하여, 일반식(Ⅰ)의 화합물 또는 이의 약학적으로 허용되는 염을 제조하는 방법.
    상기식에서, R1은 아릴 또는 일반식
    [여기서, X는 CH 또는 N이고, Z은 O 또는 N-R5(R5는 수소 또는 저급알킬임)이다]이고, R2는 하이드록시 또는 저급 알콕시이고, R3은 수소 또는 적합한 치환기(들)을 가질 수 있는 저급 알킬이고, R3 a는 보호된 하이드록시(저급)알킬이고, R3 b는 하이드록시(저급)알킬이고, R4는 적합한 치환기(들)을 가질 수 있는 아르(저급)알킬이고, A는 카르보닐 또는 술포닐이며, Y는 결합이거나 저급 알켄일렌이다.
  10. 제1항의 화합물과 약학적으로 허용되는 담체 또는 부형제를 함유하는 약학적 조성물.
  11. 제1항의 화합물을 약학적으로 허용되는 담체 또는 부형제와 혼합함을 포함하는 약학적 조성물을 제조하는 방법.
  12. 약제로서 제1항의 화합물을 사용하는 용도.
  13. 타치키닌 길항제로서 제1항의 화합물을 사용하는 용도.
  14. 물질 P 길항제로서 제1항의 화합물을 사용하는 용도.
  15. 타치키닌 매개된 질환을 치료하는 약제를 제조하기 위한 제1항의 화합물의 용도.
  16. 사람 또는 동물에게 제1항의 화합물을 투여함을 포함하는 타치키닌 매개된 질환을 치료하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900021101A 1989-12-22 1990-12-20 펩티드 화합물, 이의 제조방법 및 이를 함유하는 약학적 조성물 KR0180223B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB8929070.4 1989-12-22
GB89290704 1989-12-22
GB898929070A GB8929070D0 (en) 1989-12-22 1989-12-22 Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same

Publications (2)

Publication Number Publication Date
KR910011891A true KR910011891A (ko) 1991-08-07
KR0180223B1 KR0180223B1 (ko) 1999-04-01

Family

ID=10668423

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900021101A KR0180223B1 (ko) 1989-12-22 1990-12-20 펩티드 화합물, 이의 제조방법 및 이를 함유하는 약학적 조성물

Country Status (21)

Country Link
US (1) US5468731A (ko)
EP (1) EP0443132B1 (ko)
JP (1) JP2560919B2 (ko)
KR (1) KR0180223B1 (ko)
CN (2) CN1034869C (ko)
AT (1) ATE98651T1 (ko)
AU (1) AU640185B2 (ko)
CA (1) CA2032864C (ko)
DE (1) DE69005286T2 (ko)
DK (1) DK0443132T3 (ko)
ES (1) ES2060910T3 (ko)
FI (1) FI93548C (ko)
GB (1) GB8929070D0 (ko)
HK (1) HK18696A (ko)
HU (2) HUT56581A (ko)
IE (1) IE64570B1 (ko)
NO (1) NO177535C (ko)
PT (1) PT96324B (ko)
RU (1) RU2055078C1 (ko)
UA (1) UA27254C2 (ko)
ZA (1) ZA909901B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5966295A (en) * 1994-12-27 1999-10-12 Autonics Corporation Convertible flush or exposure type terminal board of control device

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420297A (en) * 1990-10-24 1995-05-30 Fujisawa Pharmaceutical Co., Ltd. Peptides having substance P antagonistic activity
US5610140A (en) * 1991-04-01 1997-03-11 Cortech, Inc. Bradykinin receptor antagonists with neurokinin receptor blocking activity
US5472978A (en) * 1991-07-05 1995-12-05 Merck Sharp & Dohme Ltd. Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
US5654400A (en) * 1991-10-04 1997-08-05 Fujisawa Pharmaceutical Co., Ltd. Process for making peptide compounds having tachykinin antagonistic activity
CA2324959C (en) * 1991-11-12 2002-11-12 Pfizer Limited Phthalimido compounds as intermediates for producing substance p receptor antagonists
GB9200535D0 (en) * 1992-01-10 1992-02-26 Fujisawa Pharmaceutical Co New compound
PT655055E (pt) * 1992-08-13 2001-03-30 Warner Lambert Co Antagonistas de taquiquinina
CZ127694A3 (en) * 1992-09-03 1994-11-16 Boehringer Ingelheim Kg Novel derivatives of amino acids, process of their preparation and pharmaceutical preparations in which they are comprised
DE4243496A1 (de) * 1992-09-03 1994-03-10 Boehringer Ingelheim Kg Neue Dipeptidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
FR2700472B1 (fr) 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
WO1994020126A1 (en) * 1993-03-03 1994-09-15 Fujisawa Pharmaceutical Co., Ltd. Use of peptides for the manufacture of a medicament
WO1995000536A1 (en) * 1993-06-22 1995-01-05 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds
KR960703621A (ko) * 1993-08-10 1996-08-31 후지야마 아키라 경피흡수 제제(Percutaneously absorbable preparation)
CA2174737C (en) * 1993-10-29 2008-04-22 Douglas V. Faller Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
US6403577B1 (en) 1993-11-17 2002-06-11 Eli Lilly And Company Hexamethyleneiminyl tachykinin receptor antagonists
ITFI940009A1 (it) * 1994-01-19 1995-07-19 Menarini Farma Ind Antagonisti delle tachichinine, loro preparazione e formulazioni farmaceutiche che li contengono.
DE69519182T2 (de) * 1994-03-17 2001-05-17 Fujirebio Kk Azapeptid-Derivate
FR2719312B1 (fr) * 1994-04-28 1996-06-14 Adir Nouveau pseudopeptides dérivés de neurokinines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
EP0804463A1 (de) * 1994-05-07 1997-11-05 Boehringer Ingelheim Kg Neurokinin (tachykinin)-antagonisten
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2728165A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728169A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
GB9700597D0 (en) * 1997-01-14 1997-03-05 Sandoz Pharma Uk Organic compounds
AU744261B2 (en) * 1997-04-24 2002-02-21 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating eating disorders
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
JP2002512625A (ja) * 1997-05-29 2002-04-23 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としての複素環アミド化合物
CA2298777A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating mania
CA2298779A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
GB9716457D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
KR20010033385A (ko) * 1997-12-22 2001-04-25 오노 야꾸힝 고교 가부시키가이샤 펩티드, 사람 펩시노겐 ⅱ 또는 사람 펩신 ⅱ의 측정 방법및 측정용 키트
WO1999040883A2 (en) * 1998-02-11 1999-08-19 Faller Douglas V Compositions and methods for the treatment of cystic fibrosis
WO1999064395A1 (en) * 1998-06-11 1999-12-16 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
GB9816897D0 (en) * 1998-08-04 1998-09-30 Merck Sharp & Dohme Therapeutic use
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
JP2002533338A (ja) * 1998-12-18 2002-10-08 ワーナー−ランバート・カンパニー 非ペプチドｎｋ１レセプターアンタゴニスト
AU759022B2 (en) 1999-02-18 2003-04-03 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
ATE387429T1 (de) 1999-11-03 2008-03-15 Amr Technology Inc Arly- und heteroaryl-substituierte tetrahydroisoquinoline und ihre verwendung als hemmer der wiederaufnahme von norepinephrin, dopamin und serotonin
BR0112350A (pt) 2000-07-11 2003-06-24 Albany Molecular Res Inc Composto, composição farmacêutica, e, método de tratar um animal afligido por um distúrbio neurológico ou psicológico
KR100960802B1 (ko) 2003-03-08 2010-06-01 주식회사유한양행 씨형 간염바이러스 감염 치료용 엔에스3 프로테아제 억제제
AR048401A1 (es) 2004-01-30 2006-04-26 Medivir Ab Inhibidores de la serina-proteasa ns3 del vhc
ZA200701232B (en) 2004-07-15 2008-08-27 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
US7956050B2 (en) 2005-07-15 2011-06-07 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2109608B1 (en) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
EP2129381A1 (en) 2007-01-24 2009-12-09 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2010105112A1 (en) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Detection of short-chain fatty acids in biological samples
CN102439007A (zh) 2009-03-17 2012-05-02 第一三共株式会社 酰胺衍生物
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme INHIBITORS OF AKT ACTIVITY
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
WO2010132437A1 (en) 2009-05-12 2010-11-18 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
CA2760837C (en) 2009-05-12 2018-04-03 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
EP2488028B1 (en) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
CN102802412A (zh) 2009-12-08 2012-11-28 海玛奎斯特医药公司 用于治疗红细胞病症的方法及低剂量方案
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
KR102072631B1 (ko) 2010-08-17 2020-02-03 시르나 쎄러퓨틱스 인코퍼레이티드 짧은 간섭 핵산 （ｓｉＮＡ）을 사용한 Ｂ형 간염 바이러스 （ＨＢＶ） 유전자 발현의 ＲＮＡ 간섭 매개 억제
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
US20140046059A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Process for the preparation of morpholino sulfonyl indole derivatives
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
ES2651347T3 (es) 2012-11-28 2018-01-25 Merck Sharp & Dohme Corp. Composiciones y métodos para el tratamiento del cáncer
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3976198A4 (en) 2019-05-31 2023-07-19 Viracta Subsidiary, Inc. METHODS OF TREATMENT OF VIRAL ASSOCIATED CANCER WITH HISTONE DEACETYLASE INHIBITORS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223020A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4395401A (en) * 1981-09-09 1983-07-26 Smithkline Beckman Corporation Renally active dipeptides
US5187156A (en) * 1988-03-16 1993-02-16 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same
DE3818850A1 (de) * 1988-06-03 1989-12-07 Hoechst Ag Oligopeptide mit zyklischen prolin-analogen aminosaeuren
DE3913290A1 (de) * 1989-04-22 1990-10-25 Hoechst Ag Renin-hemmende di- und tripeptide, verfahren zu deren herstellung, diese enthaltende mittel und ihre verwendung
DE3913272A1 (de) * 1989-04-22 1990-10-25 Hoechst Ag Dipeptid-derivate mit enzym-inhibitorischer wirkung
WO1991012266A1 (en) * 1990-02-15 1991-08-22 Fujisawa Pharmaceutical Co., Ltd. Peptide compound

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5966295A (en) * 1994-12-27 1999-10-12 Autonics Corporation Convertible flush or exposure type terminal board of control device

Also Published As

Publication number Publication date
FI93548B (fi) 1995-01-13
KR0180223B1 (ko) 1999-04-01
UA27254C2 (uk) 2000-08-15
HU908443D0 (en) 1991-07-29
EP0443132B1 (en) 1993-12-15
HUT56581A (en) 1991-09-30
DK0443132T3 (da) 1994-01-24
NO177535C (no) 1995-10-04
IE64570B1 (en) 1995-08-23
HU211558A9 (en) 1995-12-28
CA2032864C (en) 2003-05-06
HK18696A (en) 1996-02-09
FI906204A (fi) 1991-06-23
RU2055078C1 (ru) 1996-02-27
US5468731A (en) 1995-11-21
ES2060910T3 (es) 1994-12-01
DE69005286D1 (de) 1994-01-27
AU6801090A (en) 1991-06-27
NO905572D0 (no) 1990-12-21
ZA909901B (en) 1991-10-30
EP0443132A1 (en) 1991-08-28
PT96324B (pt) 1998-10-30
FI93548C (fi) 1995-04-25
NO177535B (no) 1995-06-26
ATE98651T1 (de) 1994-01-15
CA2032864A1 (en) 1991-06-23
JPH04210996A (ja) 1992-08-03
CN1064080A (zh) 1992-09-02
DE69005286T2 (de) 1994-04-21
CN1159949A (zh) 1997-09-24
NO905572L (no) 1991-06-24
JP2560919B2 (ja) 1996-12-04
AU640185B2 (en) 1993-08-19
GB8929070D0 (en) 1990-02-28
PT96324A (pt) 1991-09-30
FI906204A0 (fi) 1990-12-17
IE904581A1 (en) 1991-07-03
CN1034869C (zh) 1997-05-14

Similar Documents

Publication Publication Date Title
KR910011891A (ko) 펩티드 화합물, 이의 제조방법 및 이를 함유하는 약학적 조성물
Carpino et al. tert-Butyloxycarbonyl and benzyloxycarbonyl amino acid fluorides. New, stable rapid-acting acylating agents for peptide synthesis
EP0517589B1 (fr) Dérivés de tachykinines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
KR920008065A (ko) 펩타이드 화합물, 그의 제조 방법 및 그를 함유하는 약제학적 조성물
RU98104253A (ru) Новые опиоидные пептиды
DE69015244D1 (de) Peptidverbindungen, Verfahren zu deren Herstellung und pharmazeutische Präparate, die diese enthalten.
KR910011895A (ko) 약제
EP0614886B1 (en) Compound capable of intracerebral residence and use thereof
KR910009712A (ko) 세펨 화합물 및 이의 제조방법
KR960700269A (ko) 신규한 펩티드(New Peptides)
FR2579461A1 (fr) Amides de l'acide para-methoxycinnamique et de l'acide urocanique utilises comme filtres solaires; procedes d'obtention, compositions dermo-pharmaceutiques et cosmetiques les contenant et applications
GR3018096T3 (en) Polypeptide comprising repeated cell-adhesive core sequences.
KR880001677A (ko) β-락탐 화합물, 그의 제조 방법, 이를 함유하는 세균 감염성 질병 치료용 약제 및 그의 합성을 위한 중간체
DE68926981D1 (de) Cephemverbindungen und Verfahren zu ihrer Herstellung
FR2471971A1 (fr) Tetrapeptides homologues des enkephalines, leur preparation et leur utilisation therapeutique
HU186375B (en) Process for the preparation of biologically active encephalina derivatives
KR910016691A (ko) 신규한 치환된-아민 화합물 및 그의 제조방법
EP1090625B1 (en) Topical composition for the skin and use thereof
FR2471969A1 (fr) Pentapeptides homologues d'enkephalines, leur preparation et leur utilisation therapeutique
Maclaren A convenient preparative method for esters of amino acids
ATE5961T1 (de) N-acylpeptid-verbindungen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
DE59209055D1 (de) 6-Oxo-azepinoindol-Verbindungen sowie Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
FR2479827A1 (ko)
KR920006326A (ko) 새로운 아미노산 유도체, 그것의 제조방법 및 그것을 함유하는 약학적 조성물
Obase et al. New Antihypertensive Agents. II. Studies on New Analogs of 4-Piperidylbenzimidazolinones

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20031120

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee